Salesforce Delivers Mixed Financial Results And Weak Guidance
Salesforce’s (CRM) stock is down 3% after the cloud-based software company reported mixed fourth-quarter 2024 financial results and offered guidance that missed Wall Street targets.The San Francisco-based company announced earnings per share (EPS) of $2.78 U.S., which topped the consensus estimate among analysts of $2.61 U.S. However, revenue for the quarter of $10 billion U.S. slightly missed Wall Street’s forecast of $10.04 billion U.S.Salesforce has been spending heavily on artificial intelligence (A.I.), adding the technology to its suite of cloud-computing software products to automate tasks and work performed by humans. In terms of forward guidance, Salesforce said that it expects revenue in the current quarter of $9.71 billion U.S. to $9.76 billion U.S. That outlook was below the consensus view of $9.91 billion U.S. For all of this year, Salesforce sees revenue at $40.50 billion U.S. to $40.90 billion U.S., which is also short of the analyst consensus that called for $41.46 billion U.S.As for profits, Salesforce said that it expects full-year earnings per share of $11.09 U.S. to $11.17 U.S. That guidance too was below the $11.20 U.S. that Wall Street expected. The mixed results and guidance miss has Salesforce’s stock trending lower. So far in 2025, Salesforce stock has declined 7% to trade at $307.33 U.S.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


